Mesenchymal stem cells: A novel treatment option for primary sclerosing cholangitis

Lightner, Amy L.; Dadgar, Neda; Vaidya, Anil; Šimon, Róbert; Fulmer, Clifton G.; Siddiki, Hassan; Menon, Krishna; Liu, Peter; Walsh, R. Matthew

doi:10.1002/cbin.11943

Cited by 2 publications

(1 citation statement)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Biliary tract diseases, including primary sclerosing cholangitis, are a major cause of fibrosis, cirrhosis, and, in severe cases, LT. The lack of effective therapies for biliary diseases has led to the evaluation of new therapeutic options in the field of biliary regenerative medicine, which have the potential to radically change our management of these patients [ 144 , 145 ].…”

Section: Discussionmentioning

confidence: 99%

Cholangiocyte Organoids: The New Frontier in Regenerative Medicine for the Study and Treatment of Cholangiopathies

Babboni,

Vacca,

Simonini

et al. 2024

JCM

View full text Add to dashboard Cite

Cholangiopathies include a group of chronic progressive disorders, affecting the cholangiocytes, the epithelial cells that line the biliary tree, leading to liver parenchymal fibrosis and eventually end-stage liver disease necessitating transplantation. Experimental modeling of these multifactorial cholestatic diseases faces challenges due to the lack of adequate experimental in vitro and in vivo models. A novel approach employs three-dimensional organoid systems that offer several advantages for modeling disease and testing drug response in vitro. Organoids mimic intercellular communication, replicate the architecture of organs, and maintain the cell’s original phenotype. Cholangiocyte organoids provide an in vitro model to study the pathogenesis and pharmacotherapeutic treatment of cholangiopathies and show great promise for regenerative therapies. In particular, patient-derived organoids allow personalized medicine approaches and the study of individual disease characteristics. This review highlights the significance of cholangiocyte organoid models in advancing our understanding of cholangiopathies and driving advancements in regenerative medicine strategies.

show abstract

Section: Discussionmentioning

confidence: 99%

Cholangiocyte Organoids: The New Frontier in Regenerative Medicine for the Study and Treatment of Cholangiopathies

Babboni,

Vacca,

Simonini

et al. 2024

JCM

View full text Add to dashboard Cite

show abstract

Advancing Cholangiocarcinoma Care: Insights and Innovations in T Cell Therapy

Dadgar,

Arunachalam,

Hong

et al. 2024

Cancers

View full text Add to dashboard Cite

Cholangiocarcinoma (CCA) is a rare and aggressive malignancy originating from the bile ducts, with poor prognosis and limited treatment options. Traditional therapies, such as surgery, chemotherapy, and radiation, have shown limited efficacy, especially in advanced cases. Recent advancements in immunotherapy, particularly T cell-based therapies like chimeric antigen receptor T (CAR T) cells, tumor-infiltrating lymphocytes (TILs), and T cell receptor (TCR)-based therapies, have opened new avenues for improving outcomes in CCA. This review provides a comprehensive overview of the current state of T cell therapies for CCA, focusing on CAR T cell therapy. It highlights key challenges, including the complex tumor microenvironment and immune evasion mechanisms, and the progress made in preclinical and clinical trials. The review also discusses ongoing clinical trials targeting specific CCA antigens, such as MUC1, EGFR, and CD133, and the evolving role of precision immunotherapy in enhancing treatment outcomes. Despite significant progress, further research is needed to optimize these therapies for solid tumors like CCA. By summarizing the most recent clinical results and future directions, this review underscores the promising potential of T cell therapies in revolutionizing CCA treatment.

show abstract

Mesenchymal stem cells: A novel treatment option for primary sclerosing cholangitis

Cited by 2 publications

References 36 publications

Cholangiocyte Organoids: The New Frontier in Regenerative Medicine for the Study and Treatment of Cholangiopathies

Cholangiocyte Organoids: The New Frontier in Regenerative Medicine for the Study and Treatment of Cholangiopathies

Advancing Cholangiocarcinoma Care: Insights and Innovations in T Cell Therapy

Contact Info

Product

Resources

About